Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer: The type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients [1]

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 507-508

  Fietkau, Rainer ^a   Klautke, Gunther ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LETTER; LYMPH NODE; PATIENT SELECTION; PRIORITY JOURNAL; RECTUM CANCER;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 38849164357     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.0805     Document Type: Letter

References (5)

1. Collette L, Bosset JF, den Dulk M, et al: European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4379-4386, 2007
2. Collette L, Calais G, Mineur L, et al: Eur J Cancer 3:170, 2005 (suppl)
3. Fietkau R, Barten M, Klautke G, et al: Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum. 49:1284-1292, 2006
4. Rodel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688-8696, 2005
5. Liersch T, Langer C, Ghadimi BM, et al: Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 24:4062-4068, 2006